| Primary Site |
Sponsor/Study ID
NTC#
|
Protocol Description |
Eligibility |
Recurrent GBM
(Glioblastoma)
|
ECOG-ACRIN
EAF-151
NCT03115333
|
Change in Relative Cerebral Blood Volume as a Biomarker for Early Response
to Bevacizumab in Patients with Recurrent Glioblastoma |
- Histologically proven intracranial glioblastoma or gliosarcoma at initial surgery
- Karnofsky performance status >= 70
- Progression of disease assessed by Revised Assessment in Neuro-Oncology
(RANO) criteria
- Patient must not have been treated previously with immunotherapies (vaccines,
checkpoint inhibitors, T-cells)
- Intratumoral hemorrhage as seen MRI may preclude inclusion
- Progressive enhancement on MRI
- Patients must be able to tolerate brain MRI scans with dynamic intravenous
gadolinium-based contrast agent injections
- Patient must be scheduled to receive treatment with a standard dose regimen
of bevacizumab
|
Newly diagnosed GBM
(Glioblastoma)
|
Nativis
NAT-109
NCT03276286
|
A Feasibility Study of the Nativis Voyager System in Patients with Newly
Diagnosed Glioblastoma Multiforme (GBM) |
- KPS >or=60
- Pathological evidence of GBM
- Maximal debulking surgery. May enroll if received Gliadel wafers before
entering trial.
- At least 1 measurable lesion by RANO
- At least 18 years of age
- Life expectancy of > 3 months
- Adequate organ and marrow function
- Able to start treatment at least 28 days from tumor resection surgery
|
| Recurrent GBM |
Medicenna Therapeutics Inc.
MDNA55-05
NCT02858895
|
An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced
Delivery (CED) of MDNA55 in Adults with Recurrent or Progressive Glioblastoma |
- 18 years of age and life expectancy ≥ 12 weeks
- KPS ≥70
- Histological confirmed primary (de novo) GB that has recurred or progressed
(first or second recurrence, including this recurrence)
-
Access to archival tissue from 1st diagnosis of GBM
- Recurrent tumor must be suprastentorial, contrast enhancing GB no smaller
than 1 x1 cm & no larger than 4 cm max. in a single diameter based
on MRI taken within 14 days prior to catheter placement.
- Able and willing to undergo multiple brain MRI examinations
|
| Recurrent GBM |
Nativis, Inc.
NAT-101
NCT02296580
|
A Feasibility Study of the Nativis Voyager System in Patients With Recurrent
Glioblastoma Multiforme (GBM) |
- KPS ≥ 60
- Histologically confirmed diagnosis of GBM
- Failed or intolerant to: radiotherapy and temozolomide therapy
- Progressive disease with at least 1 measurable lesion on MRI
|
| Anaplastic Glioma or Low Grade Glioma |
National Cancer Institute/Alliance
N0577
NCT00887146
|
Phase III Intergroup Study of Temozolomide Alone versus Radiotherapy with
Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant
PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma
or Low Grade Glioma |
- ECOG PS: 0, 1 or 2
- Newly diagnosed and ≤ 3 months from surgical diagnosis
- Histological confirmation of anaplastic glioma or low grade glioma
- Surgery (partial or gross total resection or biopsy) performed ≥ 2 weeks
prior to registration with recovering from effects of surgery.
- Tumor must show 1p/19q codeletion
|
| Meningioma Grade II |
National Cancer Institute
NRG-BN003
NCT 03180268
|
Phase III Trial of Observation versus Irradiation for a Gross Totally Resected
grade II Meningioma |
- Newly diagnosed unifocal intracranial meningioma, gross totally resection
and histologically confirmed Grade II
- GTR must be confirmed on post-operative imaging following the most recent surgery
- Post-operative Zubrod performance status 0-1
|
| Adult Glioma and Meningioma |
National Cancer Institute / Moffitt Cancer
15004
No NCT #
|
Southeastern Study of Cancer and the Environment |
- Primary diagnosis of glioma or meningioma any grade
- GBM dx within 1 year, Anaplastic astrocytoma grade III dx within 5 years,
grate 2 or less gliomas no restrictions.
- At least 18 years of age
- Residents of the US
|
| Brain Metastasis |
NCI
A221208
NCT02490878
|
Randomized Phase II Study: Corticosteroids and Bevacizumab vs. Corticosteroids
and Placebo (BeSt) for Radionecrosis after Radiosurgery for Brain Metastases |
- Symptomatic brain radionecrosis after radiosurgery for brain metastasis
from primary solid tumor
- Radionecrosis at 3-24 months following radiosurgery
- KPS ≥ 60
- No evidence of recent hemorrhage by MRI
- No excess risk of bleeding
- No clinically significant cardiovascular disease
- No history of bowel obstruction, abdominal fistula, gastrointestinal perforation,
or intra- abdominal abscess within past 12 months
- No central lung metastases with excessive active bleeding
- No history of serious non-healing wound, ulcer, or bone fractures
|
| Brain Tumor |
NCI
A221101
NCT01781468
|
A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodafinil
(Nuvigilī) To Reduce Cancer Related Fatigue in Patients With High Grade Glioma |
- ECOG of 0, 1, 2 or 3
- Diagnosed with GBM, gliosarcoma, anaplastic astrocytoma, anaplastic oligodendroglioma
or anaplastic oligoastrocytoma who are clinically stable & have completed
radiation therapy
- Undergone surgery (gross total or subtotal resection) or biopsy and will
have been treated with concurrent radiation therapy and chemotherapy as
standard of care
- Stable dose of corticosteroid > or = 14 days prior registration
|
| Brain Tumor |
State of Florida
NCT00811148
|
Florida Center for Brain Tumor Research |
- Adults scheduled to undergo brain surgery to remove tumor tissue
|
| High grade glioma Tissue collection study |
Scripps
1R01CA229737-07
No NCT #
|
Clinical Translation of Precision Medicine Testing Utilizing 3 Dimensional
Primary Tumor Cell Culture |
- Patients scheduled to have surgery for removal of brain tumor.
- Age: 18 years and older.
|